Sudden Cardiac Death Associated with Malignant Mitral Valve Prolapse

Damon Mcenroe MD
Lehigh Valley Health Network, Damon.Mcenroe@lvhn.org

Fnu Vikram MD
Lehigh Valley Health Network, Fnu.Vikram@lvhn.org

Kailyn Mann DO
Lehigh Valley Health Network, kailyn.mann@lvhn.org

Lohit Garg MD
Lehigh Valley Health Network, lohit.garg@lvhn.org

Syed Rafay Ali Sabzwari
Lehigh Valley Health Network, Rafay.Sabzwari@lvhn.org

See next page for additional authors

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Cardiology Commons, and the Internal Medicine Commons

Published In/Presented At
Authors
Damon Mcenroe MD, Fnu Vikram MD, Kailyn Mann DO, Lohit Garg MD, Syed Rafay Ali Sabzwari, and Nael Hawwa MD

This poster is available at LVHN Scholarly Works: https://scholarlyworks.lvhn.org/medicine/1643
Sudden Cardiac Death Associated with Malignant Mitral Valve Prolapse

Damon McEnroe, MD, Fnu Vikram, MD, Kailyn Mann, DO, Lohit Garg, MD, Syed Rafay Ali Sabzwari, MD, Nael Hawwa, MD
Lehigh Valley Health Network, Allentown, Pa.

BACKGROUND
Mitral Valve Prolapse (MVP) is caused by myxomatous valve leaflet changes. Malignant MVP is an understated cause of sudden cardiac death (SCD).

CASE
A 56 year old Female with history of MVP presented as a witnessed cardiac arrest while golfing. Patient received bystander CPR and was defibrillated once for Vfib with ROSC. EKG showed Non Sustained Ventricular Tachycardia (Figure 2). Patient completed therapeutic hypothermia with full neurologic recovery. Work up showed normal coronaries, Cardiac MRI with bileaflet MVP with moderate MR and mild inferobasilar scar (Figure 4), Mitral annular disjunction (Figure 5), normal ventricular size and systolic function.

CONCLUSION
The patient had a previous Holter monitor with 3.7% PVC burden; with couplets and one triplet (figure 3), and was started on B blockers.

Malignant phenotype of MVP includes:
- Young women
- Bileaflet prolapse
- Biphasic or inverted T waves
- Complex ventricular ectopy.

The triad of substrate, trigger and transient excitation increase risk of SCD. MVP patients with scar have 7.7% risk of arrhythmic events compared to 2.5%.

Overall risk for SCD has been described around 0.4%. The patient received an ICD for secondary prevention of SCD.

DISCUSSION
MVP has been associated with SCD, necessitating a formal risk stratification strategy. This includes Holter monitor, CMR for scar and more recently PET is being studied to detect stage of inflammation. Above information can be used to guide decision and timing for Mitral valve intervention. Additionally, successful treatment with catheter ablation has been described.

DISCLOSURES
No financial disclosures for Damon McEnroe, Fnu Vikram

REFERENCES

RESULTS

Figure 2: EKG on arrival in Emergency Department.

Figure 3: Ventricular triplet demonstrated on Holter Monitor months prior to the event.

Figure 4: Cardiac MRI with late gadolinium enhancement, that is indicative of scar.

Figure 5: Mitral Annulus Disjunction on Cardiac MRI.

Figure 1: Baseline EKG.